Abstract:In gene therapy, delivery vectors are a key component for successful gene delivery and safety, based on which adeno-associated viruses (AAVs) gained popularity in particular for the liver, but also for other organs. Traditionally, rodents have been used as animal models to develop and optimize treatments, but species and organ specific tropism of AAV desire large animal models more closely related to humans for preclinical in-depth studies. Relevant AAV variants with the potential for clinical translation in liver gene therapy were previously evolved in vivo in a xenogeneic mouse model transplanted with human hepatocytes. Here, we selected and evaluated efficient AAV capsids using chimeric mice with a >90% xenografted pig hepatocytes. The pig is a valuable preclinical model for therapy studies due to its anatomic and immunological similarities to humans. Using a DNA-barcoded recombinant AAV library containing 47 different capsids and subsequent Illumina sequencing of barcodes in the AAV vector genome DNA and transcripts in the porcine hepatocytes, we found the AAVLK03 and AAVrh20 capsid to be the most efficient delivery vectors regarding transgene expression in porcine hepatocytes. In attempting to validate these findings with primary porcine hepatocytes, we observed capsid-specific differences in cell entry and transgene expression efficiency where the AAV2, AAVAnc80, and AAVDJ capsids showed superior efficiency to AAVLK03 and AAVrh20. This work highlights intricacies of in vitro testing with primary hepatocytes and the requirements for suitable pre-clinical animal models but suggests the chimeric mouse to be a valuable model to predict AAV capsids to transduce porcine hepatocytes efficiently.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to find adeno - associated virus (AAV) capsids that can effectively transduce porcine hepatocytes in gene therapy. Specifically, the researchers used a chimeric mouse model, in which the liver was replaced by more than 90% xenotransplanted porcine hepatocytes, to screen and evaluate the transduction efficiency of multiple AAV capsids in porcine hepatocytes. Through this method, the researchers hope to find highly efficient AAV capsids suitable for clinical translation, especially for the application of liver gene therapy. ### Research Background and Objectives 1. **Challenges in Gene Therapy** - In gene therapy, the delivery vector is a key factor for successful delivery and safety. AAV has become the most commonly used gene delivery vector because of its high safety and high tissue - specific transduction efficiency. - Although traditional mouse models have provided important information in preliminary studies, their immune systems and organ specificities are significantly different from those of humans. Therefore, large - animal models closer to humans are required for in - depth pre - clinical studies. 2. **Selection of Pigs as Models** - Pigs are highly similar to humans in terms of anatomy, immunology, etc., and are an ideal large - animal model. - Previous studies have used xenotransplanted mouse models to screen and optimize AAV capsids, but these models have mainly focused on human hepatocytes. 3. **Research Objectives** - Screen out AAV capsids that can be efficiently transduced in porcine hepatocytes through the chimeric mouse model. - Verify the transduction efficiency of these capsids in primary porcine hepatocytes and explore their performance in in - vitro tests. ### Main Methods 1. **Establishment of the Chimeric Mouse Model** - Use FRGN mice (fumarylacetoacetate hydrolase (Fah - / -), Rag2 - / -, Ilr2g - / - NOD - ) as models. These mice are highly immunodeficient and suffer from tyrosinemia type I, allowing xenotransplanted porcine hepatocytes to be successfully implanted and occupy the liver after the removal of Nitisinon (NTBC). - Screen out the most efficient AAV capsids by injecting a DNA - barcoded AAV library (containing 47 different capsids) through the tail vein. 2. **In - vitro Verification** - Use primary porcine hepatocytes (1°PH) for in - vitro experiments to further verify the transduction efficiency of the screened AAV capsids. - Evaluate the transduction efficiency and transgenic expression levels of different AAV capsids by methods such as fluorescence - activated cell sorting (FACS) and quantitative PCR (qPCR). ### Main Findings 1. **Results of In - vivo Screening** - Through DNA - barcoding sequencing, it was found that AAVLK03 and AAVrh20 are the most effective AAV capsids, which can efficiently transduce and express transgenic genes in porcine hepatocytes. 2. **Results of In - vitro Verification** - In in - vitro experiments, AAV2, AAVAnc80 and AAVDJ showed higher transduction efficiency and transgenic expression levels than AAVLK03 and AAVrh20. - These results emphasize the differences between in - vivo and in - vitro experiments and highlight the importance of using appropriate large - animal models for gene therapy research. ### Conclusion This study successfully screened out AAV capsids that can be efficiently transduced in porcine hepatocytes through the chimeric mouse model, providing an important reference for future pre - clinical studies of liver gene therapy. At the same time, the study also revealed the complexity between in - vivo and in - vitro experiments and emphasized the importance of standardized experimental methods and models.

AAV Capsid Screening for Translational Pig Research Using a Mouse Xenograft Liver Model